Cryptococcal Meningitis (Cryptococcus neoformans)

For the why behind the fact

Use this page to connect what you are memorizing.

Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.

Overview


Plain-Language Overview

Cryptococcal Meningitis is a serious infection that affects the brain and spinal cord, caused by the fungus Cryptococcus neoformans. This infection primarily impacts the central nervous system, leading to inflammation of the protective membranes around the brain and spinal cord, known as the meninges. It most commonly occurs in people with weakened immune systems, such as those with HIV/AIDS. Symptoms often include headache, fever, neck stiffness, and confusion. If untreated, it can cause severe neurological damage or death. Diagnosis requires specialized tests to detect the fungus in the spinal fluid. Treatment involves powerful antifungal medications to control the infection.

Clinical Definition

Cryptococcal Meningitis is a life-threatening fungal infection characterized by inflammation of the meninges caused by the encapsulated yeast Cryptococcus neoformans. It predominantly affects immunocompromised patients, especially those with CD4+ T-cell depletion such as in HIV/AIDS or organ transplant recipients on immunosuppressants. The fungus enters the central nervous system via hematogenous spread after inhalation of spores, leading to meningeal inflammation and increased intracranial pressure. Clinical features include subacute headache, fever, neck stiffness, altered mental status, and sometimes cranial nerve palsies. The infection is notable for its ability to evade host immunity through a polysaccharide capsule and melanin production. Without prompt diagnosis and treatment, it can cause meningoencephalitis, hydrocephalus, and death.

Inciting Event

  • Inhalation of Cryptococcus neoformans spores from environmental sources initiates infection.

  • Environmental reservoirs include soil, decaying wood and bird-dropping-contaminated material; a specific exposure is often not recalled.

  • Reactivation of latent infection can occur in immunosuppressed patients leading to CNS disease.

  • After dissemination, the yeast can cross into the CNS; a preexisting blood-brain barrier injury is not required.

  • Recent initiation or escalation of immunosuppressive therapy can precipitate symptomatic disease.

Latency Period

  • The incubation interval is not well established; symptoms may develop weeks to months after acquisition or after later reactivation.

  • In immunocompromised patients, progression to meningitis can be rapid within days to weeks.

  • In immunocompetent hosts, latency may be prolonged with subacute or chronic symptoms.

  • Reactivation disease may occur months to years after initial exposure.

  • Delayed diagnosis often reflects slow symptom progression and nonspecific early signs.

Diagnostic Delay

  • Nonspecific symptoms such as headache and fever often mimic viral or bacterial meningitis, delaying suspicion.

  • Low index of suspicion in non-HIV patients leads to missed early diagnosis.

  • Limited access to cryptococcal antigen testing or lumbar puncture in resource-poor settings causes delays.

  • Misinterpretation of cerebrospinal fluid findings as viral meningitis can postpone antifungal treatment.

  • Overlap with other opportunistic infections in immunocompromised hosts complicates diagnosis.

Clinical Presentation


Signs & Symptoms

  • Headache is the most common presenting symptom due to meningeal inflammation and increased intracranial pressure.

  • Fever is present in most patients but may be subtle in immunocompromised hosts.

  • Neck stiffness may occur but is often absent in advanced HIV despite meningitis.

  • Photophobia and nausea/vomiting are common due to meningeal involvement.

  • Altered mental status including confusion, lethargy, or coma occurs in advanced disease.

History of Present Illness

  • Gradual onset of headache, fever, and malaise over days to weeks is typical.

  • Progressive neurological symptoms including neck stiffness, photophobia, and altered mental status develop as meningitis worsens.

  • Nausea, vomiting, and cranial nerve palsies may occur due to increased intracranial pressure.

  • Subacute cognitive decline or personality changes can be presenting features in chronic cases.

  • Respiratory symptoms may precede CNS manifestations if pulmonary infection is present.

Past Medical History

  • Known HIV infection with low CD4 count or AIDS diagnosis is highly relevant.

  • History of organ transplantation or chronic immunosuppressive therapy increases risk.

  • Previous opportunistic infections or fungal infections suggest immunodeficiency.

  • Chronic illnesses such as diabetes or malignancy may predispose to infection.

  • Prior exposure to environments with bird droppings or soil contaminated with Cryptococcus spores.

Family History

  • []

Physical Exam Findings

  • Nuchal rigidity may be absent; a normal meningeal examination does not exclude cryptococcal meningitis.

  • Altered mental status ranging from confusion to coma may be observed in advanced cases.

  • Fever is frequently present but may be low-grade or absent in immunocompromised patients.

  • Papilledema may be seen due to increased intracranial pressure.

  • Focal neurological deficits such as cranial nerve palsies can occur with basal meningeal involvement.

Diagnostic Workup


Diagnostic Criteria

Evaluate suspected disease with CSF cryptococcal antigen (CrAg), fungal culture and opening pressure, alongside cell count, glucose and protein when LP is safe. Blood CrAg helps detect dissemination but alone does not localize infection to the CNS. India ink can show encapsulated budding yeast but is less sensitive, especially at low fungal burden. Advanced HIV may produce little CSF inflammation. Imaging evaluates complications rather than excluding meningitis by a normal scan.

Pathophysiology


Key Mechanisms

  • Inhalation of airborne Cryptococcus neoformans spores leads to pulmonary infection and hematogenous dissemination to the central nervous system.

  • Polysaccharide capsule of Cryptococcus neoformans inhibits phagocytosis and promotes immune evasion.

  • Meningeal invasion causes inflammation and increased intracranial pressure, leading to neurological symptoms.

  • Impaired cell-mediated immunity, especially defective T-cell responses, allows uncontrolled fungal proliferation in the CNS.

  • Formation of cryptococcomas and gelatinous pseudocysts disrupts normal brain architecture and function.

InvolvementDetails
Organs

Brain is the primary organ affected, with cryptococcal invasion causing meningoencephalitis and increased intracranial pressure

Lungs serve as the initial site of Cryptococcus neoformans inhalation and primary infection before dissemination

Tissues

Meninges are inflamed in cryptococcal meningitis, leading to symptoms of headache, neck stiffness, and altered mental status

Cells

Macrophages phagocytose Cryptococcus neoformans but may serve as a reservoir for fungal persistence

T lymphocytes mediate adaptive immune response critical for fungal clearance, especially CD4+ cells

Neutrophils contribute to initial innate immune response but are less effective against encapsulated fungi

Chemical Mediators

Interferon-gamma enhances macrophage fungicidal activity and is important for controlling cryptococcal infection

Tumor necrosis factor-alpha promotes inflammatory response and granuloma formation in cryptococcal meningitis

Cryptococcal polysaccharide capsule antigen is a key virulence factor and diagnostic marker detected in cerebrospinal fluid

Treatments


Pharmacological Treatments

  • Liposomal amphotericin B

    • Mechanism:
      • Binds ergosterol in fungal cell membranes causing pore formation and cell death

    • Side effects:
      • Nephrotoxicity

      • Infusion-related reactions

      • Electrolyte imbalances

    • Clinical role:
      • Preferred induction component with flucytosine in resource-available settings, usually at least 2 weeks with duration tailored to host and response. WHO HIV regimens also include a single high dose with 14 days of flucytosine plus fluconazole.

  • Flucytosine

    • Mechanism:
      • Inhibits fungal DNA and RNA synthesis by conversion to 5-fluorouracil inside fungal cells

    • Side effects:
      • Bone marrow suppression

      • Gastrointestinal upset

      • Hepatotoxicity

    • Clinical role:
      • Combination induction partner for amphotericin B; renal-adjusted and monitored, not monotherapy.

  • Fluconazole

    • Mechanism:
      • Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase, impairing ergosterol synthesis

    • Side effects:
      • Hepatotoxicity

      • QT prolongation

      • Gastrointestinal upset

    • Clinical role:
      • Consolidation followed by maintenance after induction; also part of specified alternative/WHO induction regimens.

Non-pharmacological Treatments

  • Measure opening pressure and use repeated therapeutic LPs for raised pressure as indicated; refractory cases may need CSF diversion. Pressure control is essential alongside antifungals. Routine acetazolamide, mannitol or corticosteroids do not substitute for this approach.

Prevention


Pharmacological Prevention

  • In the United States, low CD4 count alone is not an indication for routine fluconazole primary prophylaxis when blood CrAg is negative. Positive antigen screening requires evaluation for CNS disease and appropriate preemptive or full treatment.

  • Routine cryptococcal primary prophylaxis is not generally recommended for transplant recipients. HIV prevention strategies differ by endemicity and access to CrAg screening.

  • After induction and consolidation, fluconazole maintenance prevents relapse. In HIV, stopping requires adequate treatment duration, clinical stability and sustained immune/virologic recovery on ART.

Non-pharmacological Prevention

  • Exposure cannot be completely avoided because the organism is widespread. Avoid heavy exposure to aerosolized dried bird droppings when immunocompromised.

  • Effective ART prevents future opportunistic disease, but new ART initiation during active cryptococcal meningitis is usually deferred about 4-6 weeks after starting antifungals to reduce harmful inflammatory complications.

  • Use CrAg screening in advanced HIV according to setting-specific guidelines, particularly at diagnosis or return to care; positive results prompt assessment rather than automatic low-dose prophylaxis.

  • Adjust transplant immunosuppression gradually with specialists, balancing fungal clearance, rejection and IRIS risk; avoid abrupt indiscriminate withdrawal.

Outcome & Complications


Complications

  • Increased intracranial pressure leading to brain herniation is a major cause of mortality.

  • Hydrocephalus may develop from impaired CSF flow.

  • Cranial nerve palsies due to basal meningeal inflammation.

  • Seizures can occur secondary to cortical irritation or cryptococcomas.

  • Immune reconstitution inflammatory syndrome (IRIS) may complicate treatment in HIV patients starting antiretroviral therapy.

Short-term Sequelae Long-term Sequelae
  • Persistent headache due to ongoing elevated intracranial pressure despite treatment.

  • Cognitive impairment or delirium during acute illness.

  • Visual disturbances from papilledema or cranial nerve involvement.

  • Seizures during acute infection or treatment phase.

  • Chronic neurological deficits including cognitive dysfunction and focal deficits.

  • Hearing loss from cranial nerve VIII involvement.

  • Hydrocephalus requiring shunting may persist after infection resolution.

  • Post-infectious epilepsy can develop in some patients.

Differential Diagnoses


Cryptococcal Meningitis (Cryptococcus neoformans) versus Tuberculous Meningitis

Cryptococcal Meningitis (Cryptococcus neoformans)

Tuberculous Meningitis

Often subacute over days to weeks

Often subacute over weeks; tempo overlaps substantially

Variable lymphocytes, protein and glucose; inflammatory response can be sparse

Often lymphocytic with low glucose and elevated protein, but this overlaps other chronic meningitides

May have normal imaging, meningeal changes, gelatinous pseudocysts or cryptococcomas

Basal enhancement, hydrocephalus, infarcts or tuberculomas may occur

CSF CrAg and fungal culture support diagnosis; India ink is less sensitive

CSF molecular testing and mycobacterial culture support diagnosis; negative AFB or PCR does not exclude TB meningitis

Cryptococcal Meningitis (Cryptococcus neoformans) versus Bacterial Meningitis (e.g., Streptococcus pneumoniae)

Cryptococcal Meningitis (Cryptococcus neoformans)

Bacterial Meningitis (e.g., Streptococcus pneumoniae)

Often lymphocytic or paucicellular in advanced HIV

Often neutrophilic, but early disease, prior therapy and immune status alter patterns

Subacute onset with slower progression over days to weeks

Acute onset with rapid progression over hours to days

CSF glucose may be low or normal

Often low CSF-to-blood glucose ratio; degree of reduction alone does not identify the organism

Combination antifungal induction plus pressure management

Requires urgent appropriate IV antibiotics; rapid improvement is not guaranteed or a diagnostic test

Cryptococcal Meningitis (Cryptococcus neoformans) versus Viral (Aseptic) Meningitis

Cryptococcal Meningitis (Cryptococcus neoformans)

Viral (Aseptic) Meningitis

CSF glucose can be low or normal

Usually normal, but exceptions occur

Variable lymphocytes/protein and sometimes little inflammation

Often lymphocytic with modest protein elevation; substantial overlap precludes diagnosis from this alone

Usually progressive without effective antifungals

Many mild cases resolve, but herpesvirus and other severe infections may need specific therapy

Cryptococcal Meningitis (Cryptococcus neoformans) versus Neurosyphilis

Cryptococcal Meningitis (Cryptococcus neoformans)

Neurosyphilis

Environmental acquisition is common without a remembered exposure

Reactive syphilis serology and compatible findings matter; a remembered sexual exposure is not required

CSF CrAg/culture support diagnosis; India ink may be negative

CSF-VDRL is specific but insensitive in the appropriate context; a negative result does not exclude neurosyphilis

Often subacute, but course varies

Can occur at any stage of syphilis, including early meningitis; not restricted to years-late disease

Cryptococcal Meningitis (Cryptococcus neoformans) versus CNS Lymphoma (Primary or Secondary)

Cryptococcal Meningitis (Cryptococcus neoformans)

CNS Lymphoma (Primary or Secondary)

Meningeal changes or pseudocysts may occur; mass-forming cryptococcomas are possible

Enhancing mass lesions often raise concern, but leptomeningeal disease and imaging overlap occur

CSF positive for cryptococcal antigen or yeast on India ink

Biopsy showing malignant lymphoid cells

Commonly occurs in immunocompromised with meningeal infection pattern

Often occurs in immunocompromised patients but may present with mass lesions